Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections

• Egile Nagusiak: Sumonrat Chuwongwattana (Egilea), Thawinee Jantararoungtong (Egilea), Santirat Prommas (Egilea), Sadeep Medhasi (Egilea), Apichaya Puangpetch (Egilea), Chonlaphat Sukasem (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2020-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Voriconazole is the first‐line antifungal choice in the treatment of invasive fungal infections (IFIs). Single nucleotide polymorphisms (SNPs) in drug‐metabolizing and transporter genes may affect voriconazole pharmacokinetics. This study aimed to determine the frequency of the CYP2C19 rs42...